menu
    • menu
    [{"orgOrder":0,"company":"EnGeneIC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"E-EDV-D682","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EnGeneIC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EnGeneIC \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"EnGeneIC \/ Undisclosed"},{"orgOrder":0,"company":"EnGeneIC","sponsor":"Herbert Irving Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"E-EDV-D682","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EnGeneIC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EnGeneIC \/ Herbert Irving Comprehensive Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"EnGeneIC \/ Herbert Irving Comprehensive Cancer Center"},{"orgOrder":0,"company":"EnGeneIC","sponsor":"Johns Hopkins University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody-drug Conjugate","year":"2016","type":"Inapplicable","leadProduct":"EGFR(V)-EDV-Dox","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"EnGeneIC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EnGeneIC \/ Johns Hopkins University","highestDevelopmentStatusID":"6","companyTruncated":"EnGeneIC \/ Johns Hopkins University"},{"orgOrder":0,"company":"EnGeneIC","sponsor":"EnGeneIC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2015","type":"Inapplicable","leadProduct":"Targomirs","moa":"miRNA","graph1":"Oncology","graph2":"Phase I","graph3":"EnGeneIC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EnGeneIC \/ Engeneic","highestDevelopmentStatusID":"6","companyTruncated":"EnGeneIC \/ Engeneic"},{"orgOrder":0,"company":"EnGeneIC","sponsor":"ImmunityBio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2021","type":"Licensing Agreement","leadProduct":"EDV","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EnGeneIC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EnGeneIC \/ ImmunityBio","highestDevelopmentStatusID":"1","companyTruncated":"EnGeneIC \/ ImmunityBio"},{"orgOrder":0,"company":"EnGeneIC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"COVID-EDV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"EnGeneIC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EnGeneIC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EnGeneIC \/ Undisclosed"},{"orgOrder":0,"company":"EnGeneIC","sponsor":"David Ziegler","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Mitoxantrone","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"EnGeneIC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EnGeneIC \/ David Ziegler","highestDevelopmentStatusID":"6","companyTruncated":"EnGeneIC \/ David Ziegler"}]

    Find Clinical Drug Pipeline Developments & Deals by EnGeneIC

    Menu

    EnGeneIC

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            EnGeneIC

                            Australia arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            EnGeneIC

                            Australia arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : E-EDV-D682

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Herbert Irving Comprehensive Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EDV Nanocell Therapy with Gemcitabine & Nab-paclitaxel in Pancreatic Cancer

                            Details : E-EDV-D682 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Pancreatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            July 03, 2025

                            Lead Product(s) : E-EDV-D682

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Herbert Irving Comprehensive Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EnGeneIC

                            Australia arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            EnGeneIC

                            Australia arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COVID-EDV

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EnGeneIC Publishes The COVID-EDV Vaccine’s Novel Mechanism of Action in A Leading Immunology Journal

                            Details : This paper illustrates that the COVID-EDV vaccine is a fundamental change in thinking on how to produce an effective and inexpensive vaccine and has broad-reaching ramifications for vaccinology.

                            Product Name : COVID-EDV

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            January 31, 2023

                            Lead Product(s) : COVID-EDV

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            EnGeneIC

                            Australia arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            EnGeneIC

                            Australia arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EDV,Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : ImmunityBio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Australian Biotech EnGeneIC Strikes Landmark Deal with Major US Biotech ImmunityBio for COVID-19 Vaccine and ...

                            Details : Under the deal, EnGeneIC will grant ImmunityBio an exclusive, worldwide licence to develop, manufacture and commercialize EDV™ in combination with its anti-cancer drugs and COVID-19 vaccine.

                            Product Name : EDV

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            November 30, 2021

                            Lead Product(s) : EDV,Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : ImmunityBio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            EnGeneIC

                            Australia arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            EnGeneIC

                            Australia arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : E-EDV-D682,EDV-GC

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EnGeneIC Announces Acceptance of Abstract to the Annual Meeting of the American Society of Clinical Oncology 2...

                            Details : Abstract demonstrates promising early results from PHASE I/IIA study in patients with recurrent, metastatic pancreatic cancer.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            June 01, 2020

                            Lead Product(s) : E-EDV-D682,EDV-GC

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            EnGeneIC

                            Australia arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            EnGeneIC

                            Australia arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EGFR(V)-EDV-Dox

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Johns Hopkins University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent ...

                            Details : EGFR(V)-EDV-Dox is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            May 10, 2016

                            Lead Product(s) : EGFR(V)-EDV-Dox

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Johns Hopkins University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            EnGeneIC

                            Australia arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            EnGeneIC

                            Australia arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mitoxantrone

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : David Ziegler

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR

                            Details : Mitoxantrone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 22, 2016

                            Lead Product(s) : Mitoxantrone

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : David Ziegler

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            EnGeneIC

                            Australia arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            EnGeneIC

                            Australia arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Targomirs

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Asbestos Diseases Research Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC

                            Details : Targomirs is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Mesothelioma, Malignant.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            February 23, 2015

                            Lead Product(s) : Targomirs

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Asbestos Diseases Research Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth